Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Nat Rev Drug Discov. 2022 Feb 1;21(4):261–282. doi: 10.1038/s41573-021-00387-y

Figure 2. Mechanisms of neo-antigen-mediated tumour control.

Figure 2

Dying tumour cells release neoantigens that reach the draining lymph node either in a soluble form within the extracellular fluid or are transported from the tumour site by migratory antigen presenting cells (APCs). In the lymph node, highly specialised dendritic cells present the neoantigen on MHC-I or MHC-II molecules to naïve T cells for priming and activation. Activated neoantigen-specific CD4+ and CD8+ T cells leave the lymph node, enter the tumour and exert anti-tumour activities. APCs in the tumour microenvironment can activate antigen specific memory CD4+ and CD8+